Logo image of EVAX

EVAXION BIOTECH A/S (EVAX) Stock Fundamental Analysis

NASDAQ:EVAX - Nasdaq - US29970R2040 - ADR - Currency: USD

2.43  -0.96 (-28.32%)

Fundamental Rating

1

Overall EVAX gets a fundamental rating of 1 out of 10. We evaluated EVAX against 572 industry peers in the Biotechnology industry. EVAX has a bad profitability rating. Also its financial health evaluation is rather negative. EVAX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EVAX has reported negative net income.
EVAX had a negative operating cash flow in the past year.
In the past 5 years EVAX always reported negative net income.
In the past 5 years EVAX always reported negative operating cash flow.
EVAX Yearly Net Income VS EBIT VS OCF VS FCFEVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

EVAX has a Return On Assets of -99.83%. This is in the lower half of the industry: EVAX underperforms 76.11% of its industry peers.
With a Return On Equity value of -1213.49%, EVAX is not doing good in the industry: 84.42% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -99.83%
ROE -1213.49%
ROIC N/A
ROA(3y)-112.64%
ROA(5y)-112.89%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVAX Yearly ROA, ROE, ROICEVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

EVAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVAX Yearly Profit, Operating, Gross MarginsEVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -10K -20K -30K

More info and screens

2

2. Health

2.1 Basic Checks

EVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EVAX has been increased compared to 1 year ago.
Compared to 5 years ago, EVAX has more shares outstanding
The debt/assets ratio for EVAX is higher compared to a year ago.
EVAX Yearly Shares OutstandingEVAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M
EVAX Yearly Total Debt VS Total AssetsEVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

EVAX has an Altman-Z score of -3.37. This is a bad value and indicates that EVAX is not financially healthy and even has some risk of bankruptcy.
EVAX's Altman-Z score of -3.37 is in line compared to the rest of the industry. EVAX outperforms 45.31% of its industry peers.
A Debt/Equity ratio of 7.99 is on the high side and indicates that EVAX has dependencies on debt financing.
With a Debt to Equity ratio value of 7.99, EVAX is not doing good in the industry: 84.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 7.99
Debt/FCF N/A
Altman-Z -3.37
ROIC/WACCN/A
WACC5.22%
EVAX Yearly LT Debt VS Equity VS FCFEVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 2.80 indicates that EVAX has no problem at all paying its short term obligations.
The Current ratio of EVAX (2.80) is worse than 68.14% of its industry peers.
A Quick Ratio of 2.80 indicates that EVAX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.80, EVAX is doing worse than 65.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 2.8
EVAX Yearly Current Assets VS Current LiabilitesEVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

EVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.63%, which is quite impressive.
EPS 1Y (TTM)84.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, EVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.80% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.7%
EPS Next 2Y35.77%
EPS Next 3Y26.2%
EPS Next 5Y15.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EVAX Yearly Revenue VS EstimatesEVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M
EVAX Yearly EPS VS EstimatesEVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EVAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVAX Price Earnings VS Forward Price EarningsEVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVAX Per share dataEVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

EVAX's earnings are expected to grow with 26.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.77%
EPS Next 3Y26.2%

More info and screens

0

5. Dividend

5.1 Amount

EVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVAXION BIOTECH A/S

NASDAQ:EVAX (1/30/2025, 12:44:02 PM)

2.43

-0.96 (-28.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)N/A N/A
Inst Owners8.19%
Inst Owner Change0%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap14.25M
Analysts84.44
Price TargetN/A
Short Float %22.36%
Short Ratio2.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)111.41%
Min EPS beat(2)69.83%
Max EPS beat(2)152.99%
EPS beat(4)3
Avg EPS beat(4)54.8%
Min EPS beat(4)-5.58%
Max EPS beat(4)152.99%
EPS beat(8)6
Avg EPS beat(8)28.65%
EPS beat(12)9
Avg EPS beat(12)23.31%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)112.74%
Min Revenue beat(2)35.14%
Max Revenue beat(2)190.35%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)8.51%
EPS NQ rev (3m)8.51%
EPS NY rev (1m)0%
EPS NY rev (3m)6.09%
Revenue NQ rev (1m)765.68%
Revenue NQ rev (3m)765.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)730.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 51.28
P/FCF N/A
P/OCF N/A
P/B 11.38
P/tB 11.38
EV/EBITDA N/A
EPS(TTM)-1.46
EYN/A
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-2.63
FCFYN/A
OCF(TTM)-2.62
OCFYN/A
SpS0.05
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.83%
ROE -1213.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-112.64%
ROA(5y)-112.89%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 7.99
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.41%
Cap/Sales 23.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 2.8
Altman-Z -3.37
F-Score3
WACC5.22%
ROIC/WACCN/A
Cap/Depr(3y)153.54%
Cap/Depr(5y)142.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.1%
EPS Next Y83.7%
EPS Next 2Y35.77%
EPS Next 3Y26.2%
EPS Next 5Y15.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.56%
EBIT Next 3Y9.86%
EBIT Next 5YN/A
FCF growth 1Y37.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.33%
OCF growth 3YN/A
OCF growth 5YN/A